Development of novel clinical diagnostics and molecular medicines is key to fulfilling the promise of personalized medicine for treating cancer, heart disease, neurological disorders and other significant diseases. The identification of novel biomarkers based on disease-related genes, genetic mutations, and known genomes of infectious viruses and pathogens will require integrated technology platforms such as those developed at LC Sciences.